EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Dolores Isla iD, Alfredo Sánchez iD, Joaquín Casal, Manuel Cobo iD, Margarita Majem iD, Noemi Reguart, Jon Zugazagoitia, Reyes Bernabé iD

Journal of Clinical Medicine · 01.08.2023 · 12 (15) · 5063

DOI: 10.3390/jcm12155063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.08.2023. Verfasst von Dolores Isla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi (Spain).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There are currently three first-line immunotherapy options used as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand 1 (PD-L1) expression (≥50%). This manuscript aims to evaluate the available data on atezolizumab (AT), cemiplimab (CEMI), and pembrolizumab (PEMBRO) and to study the results obtained during pivotal trials, especially regarding patient subgroups.

Methods

Nominal group and Delphi techniques were used. Eight Spanish experts in lung cancer (the scientific committee of the project) analyzed the use of immunotherapy monotherapy as first-line treatment in patients with NSCLC and high PD-L1 expression. The expert scientific committee formulated several statements based on a scientific review and their own clinical experience. Subsequently, 17 additional Spanish lung cancer experts were selected to appraise the committee’s statements through two Delphi rounds. They completed a Delphi round via an online platform and voted according to a scale from 1 (strongly disagree) to 10 (strongly agree). The statements were approved if ≥70% of experts voted 7 or more.

Results

A total of 20 statements were proposed covering the following areas: (1) general characteristics of pivotal clinical trials; (2) overall main outcomes of pivotal clinical trials; and (3) subgroup analysis. All statements reached consensus in the first round.

Conclusions

AT, CEMI, and PEMBRO as monotherapy can be considered the standard of care in patients with advanced NSCLC and high PD-L1 expression (≥50%). Moreover, some differences noted among the drugs analyzed in this document might facilitate treatment decision-making, especially in clinically relevant patient subgroups, when using PD-1/PD-L1 inhibitors. The high level of agreement reached among experts supports the proposed statements.

Schlagwörter

Stichwörter der Autor:innen

PD-(L)1 inhibitorsconsensusefficacyfirst-line treatmentimmunotherapylung cancermonotherapynon-small cell lung cancersafety

Autor:innen und Institutionen

  • Medical Oncology Department, University Hospital Lozano Blesa, 50009 Zaragoza, Spain.
  • Medical Oncology Department, Consorci Hospitalari Provincial de Castelló, 12002 Castelló, Spain.
  • Medical Oncology Department, Hospital Álvaro Cunqueiro, Área Sanitaria de Vigo, 36213 Vigo, Spain.
  • UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Málaga, Spain.
  • IBIMA, 29010 Málaga, Spain.
  • Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

ORCID-Profile: Dolores Isla, Alfredo Sánchez, Manuel Cobo, Margarita Majem, Reyes Bernabé

Förderung

  • Sanofi (Spain)

Zitieren

APA

Isla, D., Sánchez, A., Casal, J., Cobo, M., Majem, M., Reguart, N., Zugazagoitia, J., & Bernabé, R. (2023). PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine, 12(15), 5063. https://doi.org/10.3390/jcm12155063

Vancouver

Isla D, Sánchez A, Casal J, Cobo M, Majem M, Reguart N, et al. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023;12(15):5063. doi:10.3390/jcm12155063

BibTeX
@article{Isla2023,
  author = {Isla, Dolores and Sánchez, Alfredo and Casal, Joaquín and Cobo, Manuel and Majem, Margarita and Reguart, Noemi and Zugazagoitia, Jon and Bernabé, Reyes},
  title = {PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {15},
  pages = {5063},
  doi = {10.3390/jcm12155063}
}
Kostenlos starten →